BIOMAT Database Logo BIOMAT Database Logo

On monitoring heparin therapy. 1976

P A Michelson

UI MeSH Term Description Entries
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P A Michelson
Monitoring heparin therapy.
March 1977, Wisconsin medical journal,
P A Michelson
[Monitoring heparin therapy].
January 1983, Revue medicale de Bruxelles,
P A Michelson
Monitoring heparin therapy.
January 1994, Annals of internal medicine,
P A Michelson
Monitoring heparin therapy.
January 1994, Annals of internal medicine,
P A Michelson
[Monitoring of heparin therapy].
October 1993, Minerva medica,
P A Michelson
Bedside monitoring of heparin therapy.
June 1978, American journal of surgery,
P A Michelson
[Heparin therapy and its monitoring].
February 1991, La Clinica terapeutica,
P A Michelson
Laboratory monitoring of heparin therapy.
November 1991, Clinical pharmacy,
P A Michelson
[Monitoring heparin therapy (author's transl)].
January 1978, Annales pharmaceutiques francaises,
P A Michelson
Monitoring heparin therapy: problems and promise.
July 1994, CAP today,
Copied contents to your clipboard!